000086286112/312024Q3falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesalts:segmentxbrli:purealts:patentalts:debenturealts:investoralts:additionalts:officeralts:paymentalts:installmentalts:tranchealts:landlordalts:guaranteeutr:sqftalts:insurance_policyalts:trading_dayalts:consultant00008628612023-12-312024-09-2800008628612024-11-0700008628612024-09-2800008628612023-12-300000862861us-gaap:NonrelatedPartyMember2024-09-280000862861us-gaap:NonrelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMember2024-09-280000862861us-gaap:RelatedPartyMember2023-12-300000862861alts:SeriesSMember2024-09-280000862861alts:SeriesSMember2023-12-300000862861alts:SeriesA1PreferredStockMember2024-09-280000862861alts:SeriesA1PreferredStockMember2023-12-300000862861us-gaap:SeriesBMember2023-12-300000862861us-gaap:SeriesBMember2024-09-280000862861alts:SeriesMMember2023-12-300000862861alts:SeriesMMember2024-09-2800008628612024-06-302024-09-2800008628612023-07-022023-09-3000008628612023-01-012023-09-3000008628612022-12-3100008628612023-09-300000862861alts:OtherSignificantNoncashTransactionBusinessAcquisitionMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionBusinessAcquisitionMember2023-01-012023-09-300000862861alts:OtherSignificantNoncashTransactionConsultingServicesMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionConsultingServicesMember2023-01-012023-09-300000862861alts:OtherSignificantNoncashTransactionLiabilityObligationsMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionLiabilityObligationsMember2023-01-012023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-12-300000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2023-12-300000862861us-gaap:CommonStockMember2023-12-300000862861us-gaap:AdditionalPaidInCapitalMember2023-12-300000862861us-gaap:RetainedEarningsMember2023-12-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300000862861us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-3000008628612023-12-312024-03-300000862861us-gaap:CommonStockMember2023-12-312024-03-300000862861us-gaap:RetainedEarningsMember2023-12-312024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-03-300000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-03-300000862861us-gaap:CommonStockMember2024-03-300000862861us-gaap:AdditionalPaidInCapitalMember2024-03-300000862861us-gaap:RetainedEarningsMember2024-03-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3000008628612024-03-300000862861us-gaap:CommonStockMember2024-03-312024-06-290000862861us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-2900008628612024-03-312024-06-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-03-312024-06-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-312024-06-290000862861us-gaap:RetainedEarningsMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-06-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-06-290000862861us-gaap:CommonStockMember2024-06-290000862861us-gaap:AdditionalPaidInCapitalMember2024-06-290000862861us-gaap:RetainedEarningsMember2024-06-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-2900008628612024-06-290000862861us-gaap:CommonStockMember2024-06-302024-09-280000862861us-gaap:AdditionalPaidInCapitalMember2024-06-302024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-06-302024-09-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-302024-09-280000862861us-gaap:RetainedEarningsMember2024-06-302024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-09-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-09-280000862861us-gaap:CommonStockMember2024-09-280000862861us-gaap:AdditionalPaidInCapitalMember2024-09-280000862861us-gaap:RetainedEarningsMember2024-09-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2022-12-310000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2022-12-310000862861us-gaap:CommonStockMember2022-12-310000862861us-gaap:AdditionalPaidInCapitalMember2022-12-310000862861us-gaap:RetainedEarningsMember2022-12-310000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000862861us-gaap:AdditionalPaidInCapitalMember2023-01-012023-04-0100008628612023-01-012023-04-010000862861us-gaap:CommonStockMember2023-01-012023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-01-012023-04-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-04-010000862861us-gaap:RetainedEarningsMember2023-01-012023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-04-010000862861us-gaap:CommonStockMember2023-04-010000862861us-gaap:AdditionalPaidInCapitalMember2023-04-010000862861us-gaap:RetainedEarningsMember2023-04-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-0100008628612023-04-010000862861us-gaap:AdditionalPaidInCapitalMember2023-04-022023-07-0100008628612023-04-022023-07-010000862861us-gaap:RetainedEarningsMember2023-04-022023-07-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-07-010000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-07-010000862861us-gaap:CommonStockMember2023-07-010000862861us-gaap:AdditionalPaidInCapitalMember2023-07-010000862861us-gaap:RetainedEarningsMember2023-07-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-0100008628612023-07-010000862861us-gaap:AdditionalPaidInCapitalMember2023-07-022023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-07-022023-09-300000862861us-gaap:CommonStockMember2023-07-022023-09-300000862861us-gaap:RetainedEarningsMember2023-07-022023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-09-300000862861us-gaap:CommonStockMember2023-09-300000862861us-gaap:AdditionalPaidInCapitalMember2023-09-300000862861us-gaap:RetainedEarningsMember2023-09-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000862861alts:Alt5SigmaInc.Member2024-05-152024-05-150000862861alts:Alt5SigmaInc.Member2024-05-150000862861alts:Alt5SigmaInc.Member2024-05-090000862861alts:Alt5SigmaInc.Memberus-gaap:SeriesBPreferredStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Memberalts:SeriesMPreferredStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:CommonStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Member2024-06-302024-09-280000862861alts:Alt5SigmaInc.Memberus-gaap:CustomerRelationshipsMember2024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:TradeNamesMember2024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:DevelopedTechnologyRightsMember2024-05-150000862861srt:ProFormaMember2024-06-302024-09-280000862861us-gaap:ScenarioAdjustmentMember2024-06-302024-09-280000862861alts:Alt5SigmaInc.Member2023-07-022023-09-300000862861srt:ProFormaMember2023-07-022023-09-300000862861us-gaap:ScenarioAdjustmentMember2023-07-022023-09-300000862861alts:Alt5SigmaInc.Member2023-12-312024-09-280000862861srt:ProFormaMember2023-12-312024-09-280000862861us-gaap:ScenarioAdjustmentMember2023-12-312024-09-280000862861alts:Alt5SigmaInc.Member2023-01-012023-09-300000862861srt:ProFormaMember2023-01-012023-09-300000862861us-gaap:ScenarioAdjustmentMember2023-01-012023-09-300000862861alts:SoinTherapeuticsLLCMemberalts:SeriesSConvertiblePreferredStockMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:BusinessAcquisitionConsiderationTrancheOneMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:BusinessAcquisitionConsiderationTrancheTwoMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheOneMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheOneMember2022-12-282022-12-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheTwoMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheTwoMember2022-12-282022-12-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheThreeMember2023-12-312024-09-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheThreeMember2022-12-282022-12-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2024-06-302024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-07-022023-09-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-12-312024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-01-012023-09-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-12-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2022-12-310000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-09-300000862861alts:SpyrTechnologiesIncMember2024-09-280000862861us-gaap:AssetUnderConstructionMember2024-09-280000862861us-gaap:AssetUnderConstructionMember2023-12-300000862861alts:SoinIntangiblesMember2024-09-280000862861alts:SoinIntangiblesMember2023-12-300000862861us-gaap:CustomerRelationshipsMember2024-09-280000862861us-gaap:CustomerRelationshipsMember2023-12-300000862861us-gaap:TradeNamesMember2024-09-280000862861us-gaap:TradeNamesMember2023-12-300000862861us-gaap:DevelopedTechnologyRightsMember2024-09-280000862861us-gaap:DevelopedTechnologyRightsMember2023-12-300000862861alts:PatentsAndDomainsMember2024-09-280000862861alts:PatentsAndDomainsMember2023-12-300000862861alts:SeriesGConvertiblePreferredStockMember2023-12-300000862861alts:CommonShareEquivalentsMember2023-12-300000862861alts:SeriesGConvertiblePreferredStockMember2023-12-312024-03-300000862861alts:CommonShareEquivalentsMember2023-12-312024-03-300000862861alts:SeriesGConvertiblePreferredStockMember2024-03-300000862861alts:CommonShareEquivalentsMember2024-03-300000862861alts:SeriesGConvertiblePreferredStockMember2024-03-312024-06-290000862861alts:CommonShareEquivalentsMember2024-03-312024-06-290000862861alts:SeriesGConvertiblePreferredStockMember2024-06-290000862861alts:CommonShareEquivalentsMember2024-06-290000862861alts:SeriesGConvertiblePreferredStockMember2024-09-280000862861alts:CommonShareEquivalentsMember2024-09-280000862861alts:A12DebenturesMaturingJune302024Memberalts:DebenturesMember2023-12-300000862861alts:A12DebenturesMaturingJune302025Memberalts:DebenturesMember2024-09-280000862861alts:A12DebenturesMaturingJune302025Memberalts:DebenturesMember2023-12-300000862861alts:DebenturesMember2024-09-280000862861alts:DebenturesMember2023-12-300000862861alts:DebenturesMember2018-10-012019-09-300000862861alts:DebenturesMember2024-06-302024-09-280000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:LegacySubsidiaryLoanMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacySubsidiaryLoanMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:OtherLegacyNotesPayableMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:OtherLegacyNotesPayableMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberus-gaap:LongTermDebtMember2024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:LongTermDebtMember2023-12-300000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-04-300000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-04-122024-04-120000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-06-302024-09-280000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-03-222024-03-220000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-04-102024-04-100000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:InvestorOneMember2024-08-200000862861alts:BigWarrantMemberalts:InvestorOneMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:InvestorTwoAndInvestorThreeMember2024-08-200000862861us-gaap:WarrantMemberalts:InvestorTwoAndInvestorThreeMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodOneMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodTwoMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodThreeMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861alts:BigWarrantMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodTwoMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-200000862861alts:SmallWarrantMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodTwoMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-2000008628612024-08-202024-08-200000862861alts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-09-280000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-192024-09-190000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-190000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-280000862861alts:IsaacCapitalGroupNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IsaacCapitalGroupNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-02-070000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-03-040000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2023-12-300000862861alts:NotePayableToJonIsaacConsultingAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NotePayableToJonIsaacConsultingAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-180000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2023-12-300000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-05-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-030000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-09-280000862861alts:NovalkAppsSAALLPShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NovalkAppsSAALLPShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2023-12-300000862861alts:NotesPayableRelatedPartiesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-02-070000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-182024-04-180000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-02-070000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-03-222024-03-220000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:LiveVentureIncorporatedMember2024-03-222024-03-220000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-09-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-05-282024-05-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-09-280000862861alts:SECComplaintMember2021-08-020000862861alts:SECComplaintMember2024-05-282024-05-280000862861alts:SECComplaintMember2024-05-280000862861alts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2021-02-012021-02-010000862861alts:InterestFeesAndCostsAndAttorneysFeesMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2021-02-012021-02-010000862861alts:StatutoryInterestMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2023-12-312024-09-280000862861alts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2024-04-102024-04-100000862861alts:LegalFeesMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2024-04-102024-04-100000862861alts:SkybridgeLitigationMemberalts:PromissoryNoteMember2024-04-100000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2021-04-092021-04-090000862861alts:GeoTraqLitigationMember2021-06-012021-06-010000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2021-06-012021-06-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-03-172023-03-170000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2023-03-172023-03-170000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-06-012023-06-010000862861alts:GeoTraqLitigationMemberus-gaap:CommonStockMember2023-06-012023-06-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-09-012023-09-010000862861alts:GeoTraqLitigationMemberus-gaap:CommonStockMember2023-09-012023-09-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-09-302023-09-300000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2022-10-192022-10-190000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2023-12-312024-09-280000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2024-09-280000862861alts:Main270LLCLitigationMemberalts:TrusteesMain270LlcMember2023-12-312024-09-280000862861alts:ApplianceSmartIncMemberalts:Main270LLCLitigationMemberalts:TrusteesMain270LlcMember2023-12-312024-09-280000862861alts:WestervilleSquareLitigationMemberalts:WestervilleSquareMember2023-12-312024-09-280000862861alts:WestervilleSquareLitigationMemberalts:WestervilleSquareMember2023-06-042023-06-040000862861alts:OtherCommitmentsAndLitigationCasesMemberalts:ApplianceSmartIncMember2021-01-020000862861alts:OtherCommitmentsAndLitigationCasesMember2017-12-300000862861alts:OtherCommitmentsAndLitigationCasesMemberalts:ApplianceSmartIncMember2023-12-300000862861alts:OtherCommitmentsAndLitigationCasesMember2023-12-300000862861alts:ArticlesOfIncorporationMember2024-09-280000862861us-gaap:PrivatePlacementMember2023-08-182023-08-180000862861us-gaap:PrivatePlacementMember2023-08-180000862861alts:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2023-08-180000862861us-gaap:PrivatePlacementMember2023-12-312024-03-300000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-12-312024-09-280000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-12-312024-03-300000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-10-092023-10-090000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-10-090000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-02-230000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberalts:ThirdPartyExchangeForBrokerageServicesMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-222024-03-220000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-222024-03-220000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-102024-04-100000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-04-102024-04-100000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-122024-04-120000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-04-122024-04-120000862861us-gaap:RestrictedStockUnitsRSUMemberus-gaap:RelatedPartyMemberus-gaap:CommonStockMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:SeriesVConvertiblePreferredStockMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:NorthYorkLTDMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-05-010000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-05-012024-05-010000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-05-012024-05-010000862861us-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-06-062024-06-060000862861alts:A2023EquityIncentivePlanMemberus-gaap:RelatedPartyMember2024-06-302024-09-280000862861alts:A2023EquityIncentivePlanMember2024-09-280000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2024-06-302024-09-280000862861alts:A2023EquityIncentivePlanMemberus-gaap:RelatedPartyMember2023-12-312024-09-280000862861alts:Plan2016Member2020-11-030000862861alts:Plan2016Member2020-11-040000862861alts:Plan2016Member2024-09-280000862861alts:Plan2016Member2023-12-300000862861alts:Plan2011Member2024-09-280000862861alts:Plan2011Member2023-12-300000862861alts:Plan2011Member2023-12-312024-09-2800008628612023-01-012023-12-300000862861us-gaap:EmployeeStockOptionMember2024-06-302024-09-280000862861us-gaap:EmployeeStockOptionMember2023-07-022023-09-300000862861us-gaap:EmployeeStockOptionMember2023-12-312024-09-280000862861us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000862861us-gaap:EmployeeStockOptionMember2024-09-280000862861alts:SeriesA1PreferredStockMember2023-12-312024-09-280000862861alts:SoinTherapeuticsMemberalts:SeriesSConvertiblePreferredStockMember2022-12-280000862861alts:SoinTherapeuticsMemberalts:SeriesSConvertiblePreferredStockMember2022-12-282022-12-280000862861alts:SeriesSConvertiblePreferredStockMember2024-09-280000862861alts:SeriesSConvertiblePreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesSPreferredStocksMember2023-12-312024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesSPreferredStocksMember2024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2024-06-302024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2023-07-022023-09-300000862861us-gaap:SegmentDiscontinuedOperationsMember2023-12-312024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-09-300000862861alts:BiotechnologyMember2024-06-302024-09-280000862861alts:BiotechnologyMember2023-07-022023-09-300000862861alts:BiotechnologyMember2023-12-312024-09-280000862861alts:BiotechnologyMember2023-01-012023-09-300000862861alts:FintechMember2024-06-302024-09-280000862861alts:FintechMember2023-07-022023-09-300000862861alts:FintechMember2023-12-312024-09-280000862861alts:FintechMember2023-01-012023-09-300000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2024-06-302024-09-280000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-07-022023-09-300000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-12-312024-09-280000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-09-300000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2024-06-302024-09-280000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-07-022023-09-300000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-12-312024-09-280000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-01-012023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2024-06-302024-09-280000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-07-022023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-12-312024-09-280000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-01-012023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2024-09-280000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-072024-02-070000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:UniversalLifeInsurancePolicyPolicyOneMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:UniversalLifeInsurancePolicyPolicyTwoMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2023-12-312024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:SellingEntitiesConsultantsMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:ConsultantOneMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:ConsultantOneMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:ConsultantTwoMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-08

☒    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o Yes x No

As of November 7, 2024, there were 14,069,469 outstanding shares of the registrant’s common stock, with a par value of $0.001.

The accompanying consolidated financial statements include the accounts of ALT5 Sigma Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “ALT5”). Effective July 15, 2024, the Company changed its corporate name from “JanOne Inc.” to “ALT5 Sigma Corporation,” and also changed its Nasdaq common stock ticker symbol from “JAN” to “ALTS”. The corporate name change was effected through a parent/subsidiary short-form merger of ALT5 Sigma Corporation, the Company’s wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change), whereby it merged with and into the Company, with the Company being the surviving entity, albeit with its new name.

The Company had three operating segments – Biotechnology, Fintech, and Recycling. In connection with the sale of ARCA Recycling, Inc. (“ARCA Recycling”), the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements.

During September 2019, ALT5 Sigma Corporation, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its patented product, a novel formulation of low-dose naltrexone, (“JAN123”). The product is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. The FDA has granted JAN123 Orphan Drug Designation for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.

On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3).

ARCA Recycling was the Company’s Recycling segment and provides turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Canada Inc. (“ARCA Canada”) provides turnkey recycling services for electric utility energy efficiency programs in Canada. Customer Connexx, LLC (“Connexx”) provides call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. The Company’s Board of Directors unanimously approved the Purchase Agreement and the Disposition Transaction. In connection with the disposition of ARCA Recycling, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements (see Note 4).

The Company reports on a 52- or 53-week fiscal year. The Company’s 2023 fiscal year (“2023”) ended on December 30, 2023, and the current fiscal year (“2024”) will end on December 28, 2024.

The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company’s ability to do so.

The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $2.4 million for the 39 weeks ended September 28, 2024. Additionally, as of September 28, 2024, the Company has total current assets of approximately $31.9 million and total current liabilities of approximately $42.3 million resulting in a net negative working capital of approximately $10.4 million. Cash provided by operations from continuing operations was approximately $3.7 million. Additionally, stockholders’ equity, as of September 28, 2024, is approximately $20.2 million.

The Company intends to raise funds to support future development of JAN 123 and JAN 101 and through a combination of cash flows derived from its acquisition of ALT5 (see Note 3), capital raises, and/or structured arrangements. However, the success of such funding cannot be assured.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 30, 2023.

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Certain amounts in the prior period have been reclassified to conform to the current period presentation. These reclassifications have no material effect on the reported financial results.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, the Series B Preferred Stock and Series M Preferred Stock issued in the transaction, pursuant to which the Company acquired the ALT5 Subsidiary, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.

Financial instruments consist primarily of cash equivalents, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments.

Digital assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The Company holds all digital assets in secure non-custodial wallets through the wallet services from Fireblocks. As of September 28, 2024, the outstanding balance of digital assets and other receivables was approximately $20.9 million.

Digital assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in the form of digital assets and or cash. The Company safeguards these digital assets and cash for customers and is obligated to safeguard them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets and other payables. As of September 28, 2024, the outstanding balance of digital assets and other payables was approximately $28.8 million.

Revenue recognition applies to the Company’s Fintech segment only, as the Company’s Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements:

1.Executed contracts with the Company’s customers that it believes are legally enforceable;

2.Identification of performance obligations in the respective contract;

3.Determination of the transaction price for each performance obligation in the respective contract;

4.Allocation of the transaction price to each performance obligation; and

5.Recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to each of the Company’s revenue category, is summarized below:

1.Product sales – revenue is recognized at the time of sale of equipment to the customer.

2.Service sales – revenue is recognized based on when the service has been provided to the customer.

The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis.

The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets.

The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.

The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and or blockchain mining fees.

The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU No. 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. The amendments in ASU No. 2023-08 are intended to improve the accounting for certain crypto assets by requiring an entity to measure those crypto assets at fair value each reporting period with changes in fair value recognized in net income. The amendments also improve the information provided to investors about an entity’s crypto asset holdings by requiring disclosure about significant holdings, contractual sale restrictions, and changes during the reporting period. The amendments are effective for all entities for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

On May 15, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.

As consideration under the acquisition, the Company issued 1,799,100 shares of its common stock to the legacy equity holders of the capital stock of ALT5 Subsidiary. Those shares represented approximately 19.9% of the Company's then-issued and outstanding shares of common stock. Each of the shares of the Company's newly-issued common stock was valued at $4.14, which was the Nasdaq Historical NOCP on Thursday, May 9, 2024, the day immediately prior to the date on which the agreement was executed. The Company also issued 34,207 shares of its newly-designated Series B Preferred Stock (the “Series B Stock”) to the legacy equity holders of the capital stock of ALT5. In connection with the closing of the acquisition of ALT5 Subsidiary, the Company also issued 3,200 shares of its newly-designated Series M Preferred Stock (the “Series M Stock”) to two entities that acted as finders for the transaction.

The fair value of the purchase price components outlined above was $16.0 million due to fair value adjustments for the shares of Series B Stock and Series M Stock, as detailed below (in $000’s):

Under the preliminary purchase price allocation, the Company recognized goodwill of approximately $3.8 million, which is calculated as the excess of both the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of May 10, 2024, as calculated by an independent third-party firm. Because the transaction was considered a stock purchase for tax purposes, none of the goodwill arising from the acquisition will be deductible for tax purposes. During the thirteen weeks ended September 28, 2024, the Company recorded a noncash fair value adjustment related to deferred tax liabilities in the aggregate amount of approximately $3.9 million, which was recorded to goodwill. The table below outlines the purchase price allocation of the purchase for ALT5 Subsidiary to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s):

Total purchase price									$	16,000
Accounts payable									267
Digital assets payable									16,763
Debt									7,613
Total liabilities assumed									24,643
Total consideration									40,643
Cash									5,853
Accounts receivable									2,917
Digital assets receivable									9,082
Intangible assets
Customer relationships						$	13,925
Trade names						2,675
Developed technology						1,850
Subtotal intangible assets									18,450
Other									492
Total assets acquired									36,794
Total goodwill									$	3,849

and an

The table below presents selected proforma information for the Company for the thirteen and twenty-six week periods ended September 28, 2024, assuming that the acquisition had occurred on January 1, 2023 (the beginning of the Company’s 2023 fiscal year), pursuant to ASC 805-10-50 (in $000’s). This proforma information does not purport to represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods.

(1)Adjustments are related to adjustments made for the following:

•Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date.

Effective January 24, 2024, the Company, Amol Soin (“Dr. Soin”), and Soin Therapeutics LLC, a wholly-owned subsidiary of the Company that was had acquired from Dr. Soin, entered into an amendment (the “Soin Amendment”) to the parties’ Agreement and Plan of Merger that was dated as of December 28, 2022 (the “Soin Agreement”). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0 million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the “Soin Preferred”) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8 million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.

In connection with the Soin Amendment, the Company reclassified the $3.0 million convertible tranche, originally valued at approximately $2.7 million on our balance sheet, from mezzanine equity to current liabilities, and reclassified the $10.0 million convertible tranche, originally valued at approximately $8.0 million on our balance sheet, to permanent equity. As of September 28, 2024, the outstanding balance in mezzanine equity relates to the $17.0 million convertible tranche originally valued at approximately $3.9 million.

On March 9, 2023, the Company discontinued operations of its Recycling segment as follows:

On March 9, 2023, the Company executed a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which, as of March 1, 2023, the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. As of September 28, 2024 and December 30, 2023, no Recycling assets or liabilities were included in discontinued operations.

In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the 39 weeks ended September 28, 2024 and September 30, 2023 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following:

In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 39 weeks ended September 28, 2024 and September 30, 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following:

The Company’s trade and other receivables as of September 28, 2024 and December 30, 2023, respectively, were as follows (in $000’s):

During the three months ended September 28, 2024, the Company was notified that SPYR Technologies, Inc. (“SPYR”) had ceased operations, and that no future quarterly interest payments on the promissory note for the Company’s sale of its subsidiary GeoTraq, Inc. would be made. Consequently, the Company has recorded an allowance of approximately $250,000 against the existing balance in accounts receivable related to SPYR’s interest payments.

Prepaids and other current assets as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):

Property and equipment as of September 28, 2024 and December 30, 2023 consist of the following: